BNTX Stock Analysis: BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1
- Latest close
- $96.9
- 20-day change
- -5.81%
- Trend state
- BULLISH
- Classification
- Healthcare · Biotechnology
Market context
BioNTech SE moved -5.81% over the latest 20-session window. BullRecon currently classifies the broader setup as BULLISH.
Latest report
The latest cached company filing period (FY2025 · $2.9B revenue · -$1.1B net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Health is currently the strongest dimension at 4.8/6, while Profitability is the lowest at 1.7/6. Scores are comparative research signals, not forecasts.